This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK (
Ziopharm(ZIOP - Get Report) is the next challenger to the Feuerstein-Ratain Rule.
Results from the palifosfamide phase III study in sarcoma are expected at the end of the current quarter. This is a make-or-break clinical catalyst for Ziopharm, so let's take a look at what the Feuerstein-Ratain Rule says about predicting the study outcome.
(I know you're impatient so I'll say Ziopharm's chances are somewhat better than
Celsion(CLSN - Get Report) but bear with me and read on.)
First, a reminder about the
Feuerstein-Ratain (F-R) Rule: University of Chicago oncologist and professor Dr. Mark Ratain and I examined 59 phase III clinical trials of cancer drugs going back 10 years. We found companies with micro-cap market valuations (i.e. market caps less than $300 million) had no chance -- 0% -- of producing positive phase III results.
By contrast, almost 80% of companies with market values greater than $1 billion conducted positive phase III studies. For companies with market values between $300 million and $1 billion, the success rate was 17%.
Importantly, Ratain and I used market values of cancer drug companies four months prior to the release of phase III results. Our findings were published in the
Journal of the National Cancer Institute.
The F-R Rule was constructed retrospectively, meaning we used old data to form our hypothesis. But since last year, two prospective challenges -- the unsuccessful phase III trials of
Keryx Pharmaceuticals'(KERX - Get Report) perifosine and Celsion's Thermodox -- confirmed the hypothesis behind the F-R Rule.
Which brings us to Ziopharm. Last November, Ziopharm announced the expectation of top-line results from the palifosfamide study in sarcoma "at the end of the first quarter 2013."
For purposes of this analysis, I'm going to assume palifosfamide results could come at any time during March, the last month of the first quarter. Per the F-R Rule, we need to examine Ziopharm's market value in November 2012 -- four months prior to the expected palifosfamide results.
Ziopharm's average share price during November 2012 was $4.45. An outstanding share count of 78.7 million (taken from the company's Sept. 30 10-Q) yields a market value of $350 million.